Among the 26 higher‐grade gliomas, 7.7% (2/26) had mutations in both IDH and TERTp, 3.8% (1/26) had mutations in IDH only, 19.2% (5/26) were wild‐type IDH and TERTp, and 69.2% (18/26) had mutations in TERTp only (Figure 1). This evidence concerns the gene IDH1 and central nervous system cancer.